CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
39.59BINR414.90M · vs all stocks (USD)
Trailing P/E
42.44xRevenue (TTM)
3.54BINR37.13M · vs all stocks (USD)
Profit Margin
26.30%Beta
0.2610xvs all stocks
52-Week Change
45.60%vs all stocks
Market Capitalization
39.59BINR414.90M · vs all stocks (USD)
Enterprise Value
32.93BINR345.11M · vs all stocks (USD)
Trailing P/E
42.44xPEG Ratio
-54.70xPrice to Sales (TTM)
11.17xPrice to Book (MRQ)
4.84xEnterprise to Revenue
9.29xEnterprise to EBITDA
34.99xGross Margin
42.37%Profit Margin
26.30%Operating Margin
22.31%Return on Assets (TTM)
5.98%Return on Equity (TTM)
11.63%Revenue (TTM)
3.54BINR37.13M · vs all stocks (USD)
Revenue per Share (TTM)
143.51INRUpdated Jul 17, 2026Quarterly Revenue Growth
8.00%Gross Profit (TTM)
1.56BINR16.34M · vs all stocks (USD)
EBITDA (TTM)
1.34BINR14.02M · vs all stocks (USD)
Net Income (TTM)
931.80MINR9.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-13.80%Operating Cash Flow (TTM)
467.30MINR4.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
700.16MINR7.34M · vs all stocks (USD)
Revenue
3.54BINRFY2026 · Mar 31, 2026Cost of Goods Sold
1.98BINRFY2026 · Mar 31, 2026Gross Profit
1.56BINRFY2026 · Mar 31, 2026Operating Income
920.20MINR9.64M · vs all stocks (USD)
Pre-tax Income
1.30BINRFY2026 · Mar 31, 2026Income Tax Expense
364.80MINRFY2026 · Mar 31, 2026Net Income
931.80MINRFY2026 · Mar 31, 2026EBIT
1.31BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
1.33BINRFY2026 · Mar 31, 2026Other Operating Expenses
409.10MINRFY2026 · Mar 31, 2026Non-operating Interest Income
13.30MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
12.60MINRFY2026 · Mar 31, 2026EPS (Basic)
37.74INRFY2026 · Mar 31, 2026EPS (Diluted)
37.74INRFY2026 · Mar 31, 2026Basic Shares Outstanding
24.69MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
24.69MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
803.90MINRFY2026 · Mar 31, 2026Free Cash Flow
800.70MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
525.00MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
1.30BINRFY2026 · Mar 31, 2026Stock-based Compensation
2.70MINRFY2026 · Mar 31, 2026Other Non-cash Items
-374.10MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
32.20MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-153.50MINRFY2026 · Mar 31, 2026Capital Expenditures
-3.20MINRFY2026 · Mar 31, 2026Purchase of Investments
-17.39BINRFY2026 · Mar 31, 2026Sale of Investments
17.19BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-203.40MINRFY2026 · Mar 31, 2026Common Dividends Paid
-617.30MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-617.30MINRFY2026 · Mar 31, 2026Shares Outstanding
24.69MSharesUpdated Jul 17, 2026Float Shares
6.69MSharesUpdated Jul 17, 2026% Held by Insiders
72.91%vs all stocks
% Held by Institutions
0.78%vs all stocks
Total Cash (MRQ)
6.68BINR69.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
270.52INRUpdated Jul 17, 2026Total Debt (MRQ)
32.10MINR336.41K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0039xCurrent Ratio (MRQ)
5.30xBook Value per Share (MRQ)
331.34INRUpdated Jul 17, 2026Total Assets
9.78BINR102.52M · vs all stocks (USD)
Total Current Assets
7.68BINRFY2026 · Mar 31, 2026Total Liabilities
1.60BINRFY2026 · Mar 31, 2026Total Non-current Assets
2.10BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
154.70MINRFY2026 · Mar 31, 2026Total Current Liabilities
1.45BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
525.00MINRFY2026 · Mar 31, 2026Other Short-term Investments
6.16BINRFY2026 · Mar 31, 2026Accounts Receivable
370.50MINRFY2026 · Mar 31, 2026Inventory
533.20MINRFY2026 · Mar 31, 2026Accounts Payable
546.50MINRFY2026 · Mar 31, 2026Short-term Debt
16.40MINRFY2026 · Mar 31, 2026Other Current Liabilities
35.90MINRFY2026 · Mar 31, 2026Long-term Debt
15.70MINRFY2026 · Mar 31, 2026Common Stock (Book)
123.40MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
8.18BINR85.71M · vs all stocks (USD)
52-Week Low
750.00INRUpdated Jul 17, 202652-Week High
1.72KINRUpdated Jul 17, 202652-Week Change
45.60%vs all stocks
Beta
0.2610xvs all stocks
50-Day MA
1.38KINRUpdated Jul 17, 2026200-Day MA
998.18INRUpdated Jul 17, 2026Avg 10-Day Volume
4.27KSharesUpdated Jul 17, 2026Avg 30-Day Volume
2.78KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
37.78INRUpdated Jul 17, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Cash Increase With FCF And Debt Decrease
Cash up four years running while long-term debt fell for three.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.83
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tenax Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Garware Hi-Tech Films Ltd.
2 interpretationsMulti-Year Cash Increase With FCF And Debt DecreaseMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cupid Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
King Slide Works Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities